Generic registration in the UAE turns on one question: does your dossier prove bioequivalence against the innovator product? The rule is simpler than many manufacturers expect. The BE evidence belongs inside the CTD dossier, and no local UAE studies are required. This explainer covers the requirement, where it sits in the pathway, and the gaps that delay files.
Why bioequivalence matters for generics
A generic product contains the same active substance as an originator medicine that has already proven its safety and efficacy. Rather than repeating the full clinical programme, the generic manufacturer demonstrates bioequivalence (BE): evidence that the generic behaves in the body the same way as the reference product. If the two are bioequivalent, the innovator's clinical record can stand behind the generic.
That makes the BE study the scientific heart of a generic application. Reviewers read it closely, and weaknesses in it are the most common reason a generic file slows down.
It is also the part of the file that is hardest to fix late. A dossier gap in administrative documents can be closed in days. A comparator problem in a completed study cannot, because the study itself would need to be repeated. For that reason we look at the BE package first, before any other part of a generic project is scoped.
The UAE requirement
For generic products registered in the UAE, BE studies against the innovator product must be included in the CTD dossier. Two points inside that sentence do most of the work.
First, the comparator. The studies must be run against the innovator product, not against another generic or a convenient local alternative. Second, the format: the evidence is submitted inside the dossier. There is no requirement to run local UAE BE studies. A well-conducted BE package prepared for your existing markets can support the UAE file, provided the comparator rule is met and the reports are complete.
BE for UAE generics, in brief
- BE studies against the innovator product must be included in the CTD dossier
- No local UAE BE studies are required
- Product registration sits with the Emirates Drug Establishment (EDE) under the law in force from 2025
- Registration certificates are valid for 5 years
- Dossiers, labels, and leaflets must be available in English and Arabic
Where BE sits in the registration pathway
The BE package is one component of a longer sequence. For a first-time foreign manufacturer, the pathway runs in this order.
Manufacturing site registration
A one-off registration per site, valid for 5 years. EDE inspections of foreign sites are at the authority's discretion, not guaranteed.
Product classification, where needed
Where the category of the product is unclear, classification is the first step before a registration file is opened.
Product registration, per product
The CTD dossier, with the BE evidence inside it, is submitted to the EDE. Pharmaceutical registration timelines vary by pathway, subject to authority response times.
Our pharmaceutical product registration service manages this sequence end to end, from site registration to certificate, with us acting as your local representative and Marketing Authorisation Holder.
Reusing an existing BE package
Because no local UAE BE studies are required, most generic manufacturers registering here are working with evidence they already own. A BE package generated for another market can support the UAE file, and in practice that is the normal route. The question is not whether to run new studies, it is whether the existing ones answer the UAE requirement as written.
Two checks settle it. Was the comparator the innovator product? And is the reporting complete enough to sit inside a CTD dossier without further explanation? Where the answer to both is yes, the BE work is done and the project becomes a dossier assembly exercise. Where the answer to either is no, it is far better to know that at the planning stage than after a submission has been made.
The rest of the file follows the standard UAE requirements. Dossiers, labels, and leaflets must be available in English and Arabic, and the registration certificate that results is valid for 5 years.
The gaps that delay generic files
The generic files that stall usually share the same handful of avoidable weaknesses.
- A comparator that is not the innovator product, which undermines the entire BE argument
- Incomplete study reporting inside the dossier, leaving reviewers to request what should already be there
- Inconsistencies between the product tested in the BE study and the product described elsewhere in the file
- Labels and leaflets not prepared in English and Arabic when the dossier is otherwise ready
None of these require new science to fix. They require a careful read of the file before submission, against the standard the reviewer will apply.
How we prepare a generic file
We review the BE package early, before the dossier is assembled: the comparator, the completeness of the reports, and the consistency of the product details across modules. We then build the CTD, prepare the bilingual labelling, and manage the submission and authority questions through to the certificate. As your local representative and Marketing Authorisation Holder, we also hold the registration on your behalf, so the certificate stays with you rather than with a distributor. We are a licensed partner, not a paperwork consultancy. For a specific product, request a quotation and we will map the file against the current requirements.
Explore the full service: pharmaceutical product registration
This explainer is general information, not regulatory or legal advice. UAE requirements continue to evolve under the current law; confirm the position with the relevant authority or contact our team before acting.